Trial · NCT00587678

Comprehensive Magnetic Resonance of Peripheral Arterial Disease

NCT00587678, Not applicable, Completed, University of Virginia; results first posted 2012-02-03

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Comprehensive Magnetic Resonance of Peripheral Arterial Disease. Trials, record NCT00587678. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00587678

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Comprehensive Magnetic Resonance of Peripheral Arterial Disease
NCT number: NCT00587678
Status: Completed
Phases: Not applicable
Enrollment: 85 participants, actual
Lead sponsor: University of Virginia
Conditions: Peripheral Artery Disease
Interventions: Simvastatin, Ezetimibe, Simvastatin/Ezetimibe
First posted: 2008-01-07
Last updated: 2017-08-21
Results first posted: 2012-02-03

Source ClinicalTrials.gov

Registered outcomes11

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Plaque Volume	2 years	SFA plaque volume
Primary	Perfusion Index	2 years	Perfusion index is a MRI measure of calf muscle perfusion indexed to the arterial input. The value is between 0 and 1 with 0 being worst and 1 being best.
Primary	Phosphocreatine Recovery Time Constant - the Time it Takes for Phosphocreatine Levels to Recover to Plateau.	2 years	Phosphocreatine recovery time constant is the time it takes for phosphocreatine levels to recover to plateau after the completion of exercise. This ranges from 20 to 1000 seconds. 20-40 seconds is normal and any value over 40 seconds is abnormal.
Secondary	Low Density Lipoprotein Cholesterol	2 years
Secondary	Total Cholesterol	2 years
Secondary	High Density Lipoprotein Cholesterol	2 years
Secondary	Triglycerides	2 years
Secondary	Magnetic Resonance Angiographic Index	2 years	MRA index is a measure of angiographic severity of disease. 0 = no disease and 4 is severe disease.
Secondary	Log Treadmill Exercise Time	2 years
Secondary	6-minute Walk Distance	2 years

1 to 10 of 11Source ClinicalTrials.gov

See all 11 registered outcomes

Outcomes11

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Plaque Volume	2 years	cm^3	MEAN
SECONDARY	Low Density Lipoprotein Cholesterol	2 years	mg/dl	MEAN
PRIMARY	Perfusion Index	2 years	Units on a scale (0 = worst, 1 = best)	MEAN
PRIMARY	Phosphocreatine Recovery Time Constant - the Time it Takes for Phosphocreatine Levels to Recover to Plateau.	2 years	seconds	MEAN
SECONDARY	Total Cholesterol	2 years	mg/dl	MEAN
SECONDARY	High Density Lipoprotein Cholesterol	2 years	mg/dl	MEAN
SECONDARY	Triglycerides	2 years	mg/dl	MEAN
SECONDARY	Magnetic Resonance Angiographic Index	2 years	units on scale (0 = normal, 4 = worst)	MEAN
SECONDARY	Log Treadmill Exercise Time	2 years	log time in seconds	MEAN
SECONDARY	6-minute Walk Distance	2 years	ft.	MEAN

1 to 10 of 11Source ClinicalTrials.gov

See all 11 outcomes

Results by group33

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Plaque Volume	Simvastatin 40mg	10.5	Standard Deviation 1.4	cm^3
Plaque Volume	Simvastatin 40mg/Ezetimibe 10 mg	10.5	Standard Deviation 1.3	cm^3
Plaque Volume	Ezetimibe 10mg	10.8	Standard Deviation 0.9	cm^3
Low Density Lipoprotein Cholesterol	Simvastatin 40mg	83	Standard Deviation 11	mg/dl
Low Density Lipoprotein Cholesterol	Simvastatin 40mg/Ezetimibe 10 mg	68	Standard Deviation 10	mg/dl
Low Density Lipoprotein Cholesterol	Ezetimibe 10mg	77	Standard Deviation 5	mg/dl
Perfusion Index	Simvastatin 40mg	0.34	Standard Deviation 0.19	Units on a scale (0 = worst, 1 = best)
Perfusion Index	Simvastatin 40mg/Ezetimibe 10 mg	0.37	Standard Deviation 0.13	Units on a scale (0 = worst, 1 = best)
Perfusion Index	Ezetimibe 10mg	0.54	Standard Deviation 0.20	Units on a scale (0 = worst, 1 = best)
Phosphocreatine Recovery Time Constant - the Time it Takes for Phosphocreatine Levels to Recover to Plateau.	Simvastatin 40mg	84	Standard Deviation 68	seconds

1 to 10 of 33Source ClinicalTrials.gov

See all 33 results by group

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Simvastatin 40mg	22
Overall Study	STARTED	Simvastatin 40mg/Ezetimibe 10 mg	22
Overall Study	STARTED	Ezetimibe 10mg	41
Overall Study	COMPLETED	Simvastatin 40mg	16
Overall Study	COMPLETED	Simvastatin 40mg/Ezetimibe 10 mg	18
Overall Study	COMPLETED	Ezetimibe 10mg	33
Overall Study	NOT COMPLETED	Simvastatin 40mg	6
Overall Study	NOT COMPLETED	Simvastatin 40mg/Ezetimibe 10 mg	4
Overall Study	NOT COMPLETED	Ezetimibe 10mg	8

Source ClinicalTrials.gov

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Simvastatin 40mg
Total, all-cause mortality	Simvastatin 40mg/Ezetimibe 10 mg
Total, all-cause mortality	Ezetimibe 10mg
Total, other adverse events	Simvastatin 40mg	0	22
Total, other adverse events	Simvastatin 40mg/Ezetimibe 10 mg	0	22
Total, other adverse events	Ezetimibe 10mg	0	41
Total, serious adverse events	Simvastatin 40mg	0	24
Total, serious adverse events	Simvastatin 40mg/Ezetimibe 10 mg	0	22
Total, serious adverse events	Ezetimibe 10mg	0	41

Source ClinicalTrials.gov

Papers7

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
16750698	BACKGROUND	PubMed
17178683	BACKGROUND	PubMed
17410566	BACKGROUND	PubMed
18025990	BACKGROUND	PubMed
19660694	DERIVED	PubMed
21570685	RESULT	PubMed
21867844	RESULT	PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
R01HL075792	Comprehensive Magnetic Resonance in PAD	KRAMER, CHRISTOPHER M.	UNIVERSITY OF VIRGINIA	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE	2003 to 2021

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00587678

GET https://conductscience.org/api/trials/v1/NCT00587678/results?page=2

API reference For AI assistants